Tarek Besheer

8PUBLICATIONS
10CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursEpigenetics (incl. genome methylation and epigenomics)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 16, 2020
Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.

Khaled Farid, Hatem Elalfy, Salwa M Abo El-Khair

|Jan 24, 2020
Malondialdehyde and C-reactive protein as prognostic markers of hepatocellular carcinoma.

S Elbaz, N Mousa, T Besheer

|Oct 17, 2019
Impact of Toll-like Receptors 2(TLR2) and TLR 4 Gene Variations on HCV Susceptibility, Response to Treatment and Development of Hepatocellular Carcinoma in Cirrhotic HCV Patients.

Mustafa Neamatallah, Mahmoud El-Bendary, Hatem Elalfy

|Apr 27, 2019
Genetic variants of XRCC1 and risk of hepatocellular carcinoma in chronic hepatitis C patients.

M Arafa, T Besheer, A M El-Eraky

|Sep 04, 2018
Association of genetic polymorphisms of chemokines and their receptors with clearance or persistence of hepatitis C virus infection.

M El-Bendary, M Neamatallah, H Elalfy

|Jul 12, 2018
Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization.

H Elalfy, T Besheer, M A El-Maksoud

Pageof 2

Frequent Collaborators

5 joint publications

Mahmoud El-Bendary

5 joint publications

Hatem Elalfy

2 joint publications

A Hegazy

2 joint publications

Ali Elmokadem